The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare Part-D for price negotiations, the next round of negotiations under the Inflation Reduction Act passed by President Joe Biden in 2022.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The two blockbusters Novo Nordisk medicines are among 15 additional drugs whose prices Medicare will be allowed to negotiate with drugmakers.

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.

Carrie Underwood probably had a vision of how her version of “America the Beautiful” would be received after accepting Donald Trump’s invitation to perform at his Jan. 20 inauguration. The majestic views of the Capitol overlooking the crowds and singing a patriotic song were likely what the 41-year-old country singer had in mind — instead, it …

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be targeted under legislation that’s expected save the government more than $200 billion over a decade.

The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the second round of the program Jan. 17.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in lower prices for patients, the Department of Health and Human Services confirmed Friday.

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy. Here's